* GeneDx Holdings Corp reported quarterly adjusted earnings of 4 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -82 cents. The mean expectation of six analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -27 cents to -16 cents per share.

* Revenue rose 44.2% to $76.87 million from a year ago; analysts expected $64.99 million.

* GeneDx Holdings Corp's reported EPS for the quarter was a loss of 31 cents​.

* The company reported a quarterly loss of $8.31 million.

* GeneDx Holdings Corp shares had risen by 32.1% this quarter and gained 1,938.5% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 0.8% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for GeneDx Holdings Corp is $49.50 This summary was machine generated from LSEG data October 29 at 02:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.21 0.04 Beat

Jun. 30 2024 -0.30 -0.10 Beat

Mar. 31 2024 -0.67 -0.33 Beat

Dec. 31 2023 -0.75 -0.69 Beat